MD, Associate Professor (MER Pd) in Infectious Diseases at Lausanne University Hospital (CHUV), with over 15 years of recognized expertise in Clostridioides difficile infection (CDI), fecal microbiota transplantation (FMT), and microbiota-based therapeutics.
Since 2019, Founder and Head of the Fecal Microbiota Transplantation (FMT) Center at CHUV, Lausanne — currently the only Swiss center accredited for FMT production. Responsible for the full implementation of the center, including infrastructure development, clinical workflows, donor and patient selection, long-term follow-up, pharmacovigilance, and national registry activities.
Key areas of expertise include:
• Clinical management of recurrent and severe CDI
• Fecal microbiota transplantation (FMT): clinical practice, production, quality standards, and regulatory oversight
• Live biotherapeutic products (LBPs) for CDI prevention
• Clinical trials methodology in CDI and microbiota-based interventions
• Donor screening, safety monitoring, and benefit–risk assessment
• Regulatory and reimbursement pathways for microbiota-based therapies
MD, Associate Professor (MER Pd) in Infectious Diseases at Lausanne University Hospital (CHUV), with over 15 years of recognized expertise in Clostridioides difficile infection (CDI), fecal microbiota transplantation (FMT), and microbiota-based therapeutics.
Since 2019, Founder and Head of the Fecal Microbiota Transplantation (FMT) Center at CHUV, Lausanne — currently the only Swiss center accredited for FMT production. Responsible for the full implementation of the center, including infrastructure development, clinical workflows, donor and patient selection, long-term follow-up, pharmacovigilance, and national registry activities.
Key areas of expertise include:
• Clinical management of recurrent and severe CDI
• Fecal microbiota transplantation (FMT): clinical practice, production, quality standards, and regulatory oversight
• Live biotherapeutic products (LBPs) for CDI prevention
• Clinical trials methodology in CDI and microbiota-based interventions
• Donor screening, safety monitoring, and benefit–risk assessment
• Regulatory and reimbursement pathways for microbiota-based therapies